Tibet Duo Rui Pharmaceutical Co (301075.SZ) Stock Price
Tibet Duo Rui Pharmaceutical Co Price
Revenue at Tibet Duo Rui Pharmaceutical Co has contracted by 11.0% per year over the past 7 years to 154.18 M CNY. Earnings per share have declined at 15.3% per year over the last 5 years. For Tibet Duo Rui Pharmaceutical Co, the net margin of -66.3% is down versus 12.9% a few years ago. At today's price the dividend yield works out to roughly 0.21%.
Tibet Duo Rui Pharmaceutical Co stock price
Tibet Duo Rui Pharmaceutical Co business model & stock analysis
Frequently asked questions about Tibet Duo Rui Pharmaceutical Co
Converted at the current exchange rate, the Tibet Duo Rui Pharmaceutical Co share trades at 8.06 EUR (60.60 CNY).
The revenue cannot currently be calculated for Tibet Duo Rui Pharmaceutical Co.
The profit cannot currently be calculated for Tibet Duo Rui Pharmaceutical Co.
The P/E ratio cannot be calculated for Tibet Duo Rui Pharmaceutical Co at the moment.
The P/S cannot be calculated for Tibet Duo Rui Pharmaceutical Co currently.
The Eulerpool Quality Score for Tibet Duo Rui Pharmaceutical Co is 1/10.
The ISIN of Tibet Duo Rui Pharmaceutical Co is CNE100004RW5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Tibet Duo Rui Pharmaceutical Co is 301075.SZ. The ticker symbol is used to trade Tibet Duo Rui Pharmaceutical Co shares on the stock exchange.
Tibet Duo Rui Pharmaceutical Co stock
Tibet Duo Rui Pharmaceutical Co Peer Group
Tibet Duo Rui Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Tibet Duo Rui Pharmaceutical Co
Our stock analysis for Tibet Duo Rui Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tibet Duo Rui Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.